This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Stock Mailbag: Mela, Osiris, Talon

Three chances at making the right diagnosis, MelaFind whiffs each time. Incredibly, despite the machine's 100% error rate, this New York dermatologist remained a stalwart believer. The investor asked her why she planned on using MelaFind on her patients if the results were so inaccurate. After some hemming and hawing, the doctor finally admitted that her patients are wealthy and can afford the out-of-pocket expense. In total, the doctor said she hoped to clear $40,000 to $50,000 in extra income from MelaFind, on top of the money she makes from performing biopsies.

Mela could do well with MelaFind if all dermatologists are equally greedy. Unfortunately for Mela, not all dermatologists have wealthy New York clients.

Joseph writes: "Osiris Therapeutics (OSIR - Get Report) generated a whopping $1.6 million in revenue in the second quarter. The company even had the audacity to include the following statement in its press release: 'In the largest study of allogeneic or 'off-the-shelf' stem cells ever conducted in heart-attack patients, reported interim one-year results showing that treatment with Prochymal resulted in a statistically significant reduction in heart failure in patients experiencing first-time acute myocardial infarction.' "

I sense Joseph is egging me on to dish more dirt on Osiris. OK, I'll bite. I found another example of bamboozlement and misleading statements made by Osiris' CEO, Randy Mills.

Randy, you need a fact checker on staff, full time!

The latest episode involving Mills' penchant for telling half-truths occurred during his presentation at the JMP Securities Healthcare Conference on July 13. Mills was discussing Grafix, a stem-cell-soaked bandage that Osiris has been trying to market as a wound-healing cure with little success, as witnessed by the paltry $1.6 million in second-quarter sales.

Naturally, Mills described Grafix in far more glowing terms during his investor chat. Grafix is so effective as a wound-healing agent, Mills insisted, that doctors are pushing Osiris to find new uses for it.

"It was not a long walk for physicians to start figuring out that Grafix could be used for other things, specifically in the diabetic foot ulcer and limb salvage space," Mills told investors at the JMP Securities conference, according to a recording of his presentation. "So we did a pilot trial where we showed -- I think it was a 60-patient trial -- it showed that we have a 70% closure rate in recalcitrant DFU."

Any therapy that can induce a 70% closure rate in hard-to-treat diabetic foot ulcers would be very promising indeed. Unfortunately, I looked hard to find any evidence or mention of this 60-patient pilot study of Grafix in diabetic foot ulcer patients but came up empty.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMRN $1.51 0.00%
MELA $1.77 0.00%
OSIR $17.27 0.00%
VRTX $119.43 0.00%
AAPL $128.46 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs